Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV Dec 16, 2021
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Dec 13, 2021
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Dec 10, 2021
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Dec 09, 2021
Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Dec 08, 2021
